Skip to main content
SpringerLink
Log in

An Overview of the Management of Thyroid Cancer

  • Chapter
Practical Management of Thyroid Cancer

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide Ver.1.0 JARC Cancer Base No. 5 Lyon, IARC Press, 2001. Last updated on 03/02/2001. http://www-dep.iarc.fr/globocan/globocan.html [1.0]. 2001.

    Google Scholar 

  2. Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1975–2001, National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2001/. 2004.

    Google Scholar 

  3. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence-SEER 9 Regs Public-Use, Nov 2003 Sub (1973–2001), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2004, based on the November 2003 submission. National Cancer Institute, 2004.

    Google Scholar 

  4. Colonna M, Grosclaude P, Remontet L, et al. Incidence of thyroid cancer in adults recorded by French cancer registries (1978–1997). Eur J Cancer 2002; 38(13):1762–1768.

    Article  PubMed  CAS  Google Scholar 

  5. Cotterill SJ, Pearce MS, Parker L. Thyroid cancer in children and young adults in the North of England. Is increasing incidence related to the Chernobyl accident? Eur J Cancer 2001; 37(8):1020–1026.

    Article  PubMed  CAS  Google Scholar 

  6. Liu S, Semenciw R, Ugnat AM, Mao Y. Increasing thyroid cancer incidence in Canada, 1970–1996: time trends and age-period-cohort effects. Br J Cancer 2001; 85(9):1335–1339.

    Article  PubMed  CAS  Google Scholar 

  7. Lundgren CI, Hall P, Ekbom A, Frisell J, Zedenius J, Dickman PW. Incidence and survival of Swedish patients with differentiated thyroid cancer. Int J Cancer 2003; 106(4):569–573.

    Article  PubMed  CAS  Google Scholar 

  8. Verkooijen HM, Fioretta G, Pache JC, et al. Diagnostic changes as a reason for the increase in papillary thyroid cancer incidence in Geneva, Switzerland. Cancer Causes Control 2003; 14(1):13–17.

    Article  PubMed  Google Scholar 

  9. Merhy J, Driscoll HK, Leidy JW, Chertow BS. Increasing incidence and characteristics of differentiated thyroid cancer in Huntington, West Virginia. Thyroid 2001; 11(11):1063–1069.

    Article  PubMed  CAS  Google Scholar 

  10. Huszno B, Szybinski Z, Przybylik-Mazurek E, et al. Influence of iodine deficiency and iodine prophylaxis on thyroid cancer histotypes and incidence in endemic goiter area. J Endocrinol Invest 2003; 26(2 Suppl):71–76.

    PubMed  CAS  Google Scholar 

  11. Heidenreich WF, Kenigsberg J, Jacob P, et al. Time trends of thyroid cancer incidence in Belarus after the Chernobyl accident. Radiat Res 1999; 151:617–625.

    PubMed  CAS  Google Scholar 

  12. Zheng TZ, Holford TR, Chen YT, et al. Time trend and age-period-cohort effect on incidence of thyroid cancer in Connecticut, 1935–1992. Int J Cancer 1996; 67:504–509.

    Article  PubMed  CAS  Google Scholar 

  13. Estimated exposures and thyroid doses received by the American people from iodine-131 in fallout following Nevada atmospheric nuclear bomb tests. A report from the National Cancer Institute. Washington, DC: US Department of Health and Human Services. National Institutes of Health. National Cancer Institute, 1997.

    Google Scholar 

  14. Leenhardt L, Bernier MO, Boin-Pineau MH, et al. Advances in diagnostic practices affect thyroid cancer incidence in France. Eur J Endocrinol 2004; 150(2):133–139.

    Article  PubMed  CAS  Google Scholar 

  15. 15. Institute of Medicine, Committee on Thyroid Screening Related to, National Research Council (US), Committee on Exposure of the American People to Iodine-131 from Nevada nuclear-bomb tests review of the National Cancer Institute report and public health implications. Washington, DC: National Academy Press, 1999.

    Google Scholar 

  16. Rahu M. Health effects of the Chernobyl accident: fears, rumours and the truth. Eur J Cancer 2003; 39(3):295–299.

    Article  PubMed  Google Scholar 

  17. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53 856 cases of thyroid carcinoma treated in the US, 1985–1995. Cancer 1998; 83:2638–2648.

    Article  PubMed  CAS  Google Scholar 

  18. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001; 86(4):1447–1463.

    Article  PubMed  CAS  Google Scholar 

  19. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97:418–428.

    Article  PubMed  CAS  Google Scholar 

  20. Pinn VW. Sex and gender factors in medical studies: implications for health and clinical practice. JAMA 2003; 289(4):397–400.

    Article  PubMed  Google Scholar 

  21. Kitamura Y, Shimizu K, Nagahama M, et al. Immediate causes of death in thyroid carcinoma: Clinicopathological analysis of 161 fatal cases. J Clin Endocrinol Metab 1999; 84:4043–4049.

    Article  PubMed  CAS  Google Scholar 

  22. LiVolsi VA. Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival. Cancer 2003; 98(9):1997–1998.

    Article  PubMed  Google Scholar 

  23. Burman KD, Ringel MD, Wartofsky L. Unusual types of thyroid neoplasms. Endocrinol Metabol Clin North Am 1996; 25:49–68.

    Article  CAS  Google Scholar 

  24. LiVolsi VA. Unusual variants of papillary thyroid carcinoma. In: Mazzaferri EL, Kreisberg RA, Bar RS (eds) Advances in endocrinology and metabolism. St Louis: Mosby-Year Book, Inc., 1995:39–54.

    Google Scholar 

  25. Yang GC, Liebeskind D, Messina AV. Ultrasoundguided fine-needle aspiration of the thyroid assessed by ultrafast Papanicolaou stain: data from 1135 biopsies with a two-to six-year follow-up. Thyroid 2001; 11(6):581–589.

    Article  PubMed  CAS  Google Scholar 

  26. Kesmodel SB, Terhune KP, Canter RJ, et al. The diagnostic dilemma of follicular variant of papillary thyroid carcinoma. Surgery 2003; 134(6):1005–1012.

    Article  PubMed  Google Scholar 

  27. Sobrinho-Simoes M, Soares J, Carneiro F. Diffuse follicular variant of papillary carcinoma of the thyroid: report of eight cases of a distinct aggressive type of tumor. Surg Pathol 1990; 3:189–203.

    Google Scholar 

  28. Zidan J, Karen D, Stein M, Rosenblatt E, Basher W, Kuten A. Pure versus follicular variant of papillary thyroid carcinoma. Cancer 2003; 97(5):1181–1185.

    Article  PubMed  Google Scholar 

  29. Passler C, Prager G, Scheuba C, et al. Follicular variant of papillary thyroid carcinoma: a long-term follow-up. Arch Surg 2003; 138(12):1362–1366.

    Article  PubMed  Google Scholar 

  30. Chow SM, Chan JK, Law SC, et al. Diffuse sclerosing variant of papillary thyroid carcinoma — clinical features and outcome. Eur J Surg Oncol 2003; 29(5):446–449.

    Article  PubMed  Google Scholar 

  31. Albareda M, Puig-Domingo M, Wengrowicz S, et al. Clinical forms of presentation and evolution of diffuse sclerosing variant of papillary carcinoma and insular variant of follicular carcinoma of the thyroid. Thyroid 1998; 8(5):385–391.

    PubMed  CAS  Google Scholar 

  32. Herrera MF, Hay ID, Wu PS, et al. Hurthle cell (oxyphilic) papillary thyroid carcinoma: a variant with more aggressive biologic behavior. World J Surg 1994; 16:669–674.

    Article  Google Scholar 

  33. Prendiville S, Burman KD, Ringel MD, et al. Tall cell variant: An aggressive form of papillary thyroid carcinoma. Otolaryngol Head Neck Surg 2000; 122(3):352–357.

    Article  PubMed  CAS  Google Scholar 

  34. Ferreiro JA, Hay ID, Lloyd RV. Columnar cell carcinoma of the thyroid: Report of three additional cases. Hum Pathol 1996; 27:1156–1160.

    Article  PubMed  CAS  Google Scholar 

  35. van Heerden JA, Hay ID, Goellner JR, et al. Follicular thyroid carcinoma with capsular invasion alone: A nonthreatening malignancy. Surgery 1992; 112:1130–1138.

    PubMed  Google Scholar 

  36. D’Avanzo A, Treseler P, Ituarte PH, et al. Follicular thyroid carcinoma: histology and prognosis. Cancer 2004; 100(6):1123–1129.

    Article  PubMed  Google Scholar 

  37. Thompson LD, Wieneke JA, Paal E, Frommelt RA, Adair CF, Heffess CS. A clinicopathologic study of minimally invasive follicular carcinoma of the thyroid gland with a review of the English literature 2. Cancer 2001; 91(3):505–524.

    Article  PubMed  CAS  Google Scholar 

  38. Lopez-Penabad L, Chiu AC, Hoff AO, et al. Prognostic factors in patients with Hurthle cell neoplasms of the thyroid. Cancer 2003; 97(5):1186–1194.

    Article  PubMed  Google Scholar 

  39. McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma: A 50-year experience at a single institution. Surgery 2001; 130(6):1028–1034.

    Article  PubMed  CAS  Google Scholar 

  40. Rodriguez JM, Pinero A, Ortiz S, et al. Clinical and histological differences in anaplastic thyroid carcinoma. Eur J Surg 2000; 166(1):34–38.

    Article  PubMed  CAS  Google Scholar 

  41. Voutilainen PE, Multanen M, Haapiainen RK, Leppäniemi AK, Sivula AH. Anaplastic thyroid carcinoma survival. World J Surg 1999; 23:975–979.

    Article  PubMed  CAS  Google Scholar 

  42. Miura D, Wada N, Chin K, et al. Anaplastic thyroid cancer: cytogenetic patterns by comparative genomic hybridization. Thyroid 2003; 13(3):283–290.

    Article  PubMed  CAS  Google Scholar 

  43. Camargo R, Limbert E, Gillam M, et al. Aggressive metastatic follicular thyroid carcinoma with anaplastic transformation arising from a long-standing goiter in a patient with Pendred’s syndrome. Thyroid 2001; 11(10):981–988.

    Article  PubMed  CAS  Google Scholar 

  44. Hazard JB, Hawk WA, Crile G Jr. Medullary (solid) carcinoma of the thyroid: A clinicopathologic entity. J Clin Endocrinol Metab 1959; 19:152–161.

    PubMed  CAS  Google Scholar 

  45. Williams ED. Medullary thyroid carcinoma of the thyroid gland. J Clin Pathol 1967; 20:395–398.

    Google Scholar 

  46. Melvin KE, Tashjian AH Jr. The syndrome of excessive thyrocalcitonin produced by medullary carcinoma of the thyroid. Proc Natl Acad Sci USA 1968; 59:1216–1222.

    Article  PubMed  CAS  Google Scholar 

  47. Tashjian AH Jr, Melvin EW. Medullary carcinoma of the thyroid gland. Studies of thyrocalcitonin in plasma and tumor extracts. N Engl J Med 1968; 279:279–283.

    Article  PubMed  Google Scholar 

  48. Jackson CE, Tashjian AH Jr, Block MA. Diagnostic dependability of calcitonin assay in family studies for medullary thyroid carcinoma. J Lab Clin Med 1971; 78:817–818.

    PubMed  CAS  Google Scholar 

  49. Melvin KE, Miller HH, Tashjian AH Jr. Early diagnosis of medullary carcinoma of the thyroid gland by means of calcitonin assay. N Engl J Med 1971; 285:1115–1120.

    Article  PubMed  CAS  Google Scholar 

  50. Melvin KE, Tashjian AH Jr, Miller HA. Studies in familial thyroid cancer. Trans Assoc Am Physicians 1971; 84:144–151.

    PubMed  CAS  Google Scholar 

  51. Simpson NE, Kidd KK, Goodfellow PJ, et al. Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by linkage. Nature 1987; 328:528–530.

    Article  PubMed  CAS  Google Scholar 

  52. Mathew CGP, Chin KE, Easton DF, et al. A linked genetic marker form multiple endocrine neoplasia type 2A on chromosome 10. Nature 1987; 328:527–528.

    Article  PubMed  CAS  Google Scholar 

  53. Lairmore TC, Howe JR, Korte JA, et al. Familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2B map to the same region of chromosome 10 as multiple endocrine neoplasia type 2A. Genomics 1991; 9:181–192.

    Article  PubMed  CAS  Google Scholar 

  54. Mulligan LM, Kwok JBJ, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993; 363:458–460.

    Article  PubMed  CAS  Google Scholar 

  55. Hofstra RMW, Landsvater RM, Ceccherini I, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994; 367:375–376.

    Article  PubMed  CAS  Google Scholar 

  56. Wells SA Jr, Donis-Keller H. Current perspectives on the diagnosis and management of patients with multiple endocrine neoplasia type 2 syndromes. Endocrinol Metabol Clin North Am 1994; 23:215–228.

    CAS  Google Scholar 

  57. Carlson KM, Dou S, Chi D, et al. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci USA 1994; 91:1579–1583.

    Article  PubMed  CAS  Google Scholar 

  58. Moosa M, Mazzaferri EL. Occult thyroid carcinoma. Cancer J 1997; 10:180–188.

    Google Scholar 

  59. Baudin E, Travagli JP, Ropers J, et al. Microcarcinoma of the thyroid gland — The Gustave-Roussy Institute Experience. Cancer 1998; 83:553–559.

    Article  PubMed  CAS  Google Scholar 

  60. Chow SM, Law SC, Chan JK, et al. Papillary microcarcinoma of the thyroid-prognostic significance of lymph node metastasis and multifocality. Cancer 2003; 98(1):31–40.

    Article  PubMed  Google Scholar 

  61. Sugg SL, Ezzat S, Rosen IB, Freeman JL, Asa SL. Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J Clin Endocrinol Metab 1998; 83:4116–4122.

    Article  PubMed  CAS  Google Scholar 

  62. Pacini F, Elisei R, Capezzone M, et al. Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low-and high-risk patients. Thyroid 2001; 11(9):877–881.

    Article  PubMed  CAS  Google Scholar 

  63. Scheumann GFW, Seeliger H, Musholt TJ, et al. Completion thyroidectomy in 131 patients with differentiated thyroid carcinoma. Eur J Surg 1996; 162:677–684.

    PubMed  CAS  Google Scholar 

  64. Pasieka JL, Thompson NW, McLeod MK, Burney RE, Macha M. The incidence of bilateral well-differentiated thyroid cancer found at completion thyroidectomy. World J Surg 1992; 16:711–716.

    Article  PubMed  CAS  Google Scholar 

  65. Loh KC, Greenspan FS, Gee L, Miller TR, Yeo PPB. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: A retrospective analysis of 700 patients. J Clin Endocrinol Metab 1997; 82:3553–3562.

    Article  PubMed  CAS  Google Scholar 

  66. Massin JP, Savoie JC, Garnier H, et al. Pulmonary metastases in differentiated thyroid carcinoma. Study of 58 cases with implications for the primary tumor treatment. Cancer 1984; 53:982–992.

    PubMed  CAS  Google Scholar 

  67. Machens A, Holzhausen HJ, Lautenschlager C, Thanh PN, Dralle H. Enhancement of lymph node metastasis and distant metastasis of thyroid carcinoma. Cancer 2003; 98(4):712–719.

    Article  PubMed  Google Scholar 

  68. Mirallie E, Visset J, Sagan C, Hamy A, Le Bodic MF, Paineau J. Localization of cervical node metastasis of papillary thyroid carcinoma. World J Surg 1999; 23(9):970–973.

    Article  PubMed  CAS  Google Scholar 

  69. Qubain SW, Nakano S, Baba M, Takao S, Aikou T. Distribution of lymph node micrometastasis in pN0 well-differentiated thyroid carcinoma. Surgery 2002; 131(3):249–256.

    Article  PubMed  Google Scholar 

  70. Wada N, Duh QY, Sugino K, et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg 2003; 237(3):399–407.

    Article  PubMed  Google Scholar 

  71. Arch-Ferrer J, Velazquez D, Fajardo R, et al. Accuracy of sentinel lymph node in papillary thyroid carcinoma. Surgery 2001; 130(6):907–913.

    Article  PubMed  CAS  Google Scholar 

  72. Kouvaraki MA, Shapiro SE, Fornage BD, et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 2003; 134(6):946–954.

    Article  PubMed  Google Scholar 

  73. Mazzaferri EL. Thyroid carcinoma: Papillary and follicular. In: Mazzaferri EL, Samaan N (eds) Endocrine tumors. Cambridge, MA: Blackwell Scientific Publications Inc., 1993:278–333.

    Google Scholar 

  74. Schlumberger M, Challeton C, De Vathaire F, Parmentier C. Treatment of distant metastases of differentiated thyroid carcinoma. J Endocrinol Invest 1995; 18:170–172.

    PubMed  CAS  Google Scholar 

  75. Pittas AG, Adler M, Fazzari M, et al. Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. Thyroid 2000; 10(3):261–268.

    PubMed  CAS  Google Scholar 

  76. Schlumberger M, Tubiana M, De Vathaire F, et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 1986; 63:960–967.

    PubMed  CAS  Google Scholar 

  77. Sisson JC, Giordano TJ, Jamadar DA, et al. 131-I treatment of micronodular pulmonary metastases from papillary thyroid carcinoma. Cancer 1996; 78:2184–2192.

    Article  PubMed  CAS  Google Scholar 

  78. Schlumberger MJ. Diagnostic follow-up of welldifferentiated thyroid carcinoma: Historical perspective and current status. J Endocrinol Invest 1999; 22(suppl to no. 11):3–7.

    PubMed  CAS  Google Scholar 

  79. Hung W, Sarlis NJ. Current controversies in the management of pediatric patients with well-differentiated non-medullary thyroid cancer: A review. Thyroid 2002; 12:683–702.

    Article  PubMed  Google Scholar 

  80. Cady B. Staging in thyroid carcinoma. Cancer 1998; 83:844–847.

    Article  PubMed  CAS  Google Scholar 

  81. Miccoli P, Antonelli A, Spinelli C, Ferdeghini M, Fallahi P, Baschieri L. Completion total thyroidectomy in children with thyroid cancer secondary to the Chernobyl accident. Arch Surg 1998; 133:89–93.

    Article  PubMed  CAS  Google Scholar 

  82. Belfiore A, Russo D, Vigneri R, Filetti S. Graves’ disease, thyroid nodules and thyroid cancer. Clin Endocrinol (Oxf) 2001; 55(6):711–718.

    Article  CAS  Google Scholar 

  83. Ohta K, Pang XP, Berg L, Hershman JM. Growth inhibition of new human thyroid carcinoma cell lines by activation of adenylate cyclase through the badrenergic receptor. J Clin Endocrinol Metab 1997; 82:2633–2638.

    Article  PubMed  CAS  Google Scholar 

  84. Bell B, Mazzaferri EL. Familial adenomatous polyposis (Gardner’s syndrome) and thyroid carcinoma: A case report and review of the literature. Dig Dis Sci 1993; 38:185–190.

    Article  PubMed  CAS  Google Scholar 

  85. Fagin JA. Editorial familial nonmedullary thyroid carcinoma — the case for genetic susceptibility. J Clin Endocrinol Metab 1997; 82:342–344.

    Article  PubMed  CAS  Google Scholar 

  86. Loh KC. Familial nonmedullary thyroid carcinoma: a meta-review of case series. Thyroid 1997; 7(1):107–113.

    PubMed  CAS  Google Scholar 

  87. Malchoff CD, Malchoff DM. The genetics of hereditary nonmedullary thyroid carcinoma. J Clin Endocrinol Metab 2002; 87(6):2455–2459.

    Article  PubMed  CAS  Google Scholar 

  88. Lupoli G, Vitale G, Caraglia M, et al. Familial papillary thyroid microcarcinoma: a new clinical entity. Lancet 1999; 353:637–639.

    Article  PubMed  CAS  Google Scholar 

  89. Alsanea O, Wada N, Ain K, et al. Is familial nonmedullary thyroid carcinoma more aggressive than sporadic thyroid cancer? A multicenter series. Surgery 2000; 128(6):1043–1050.

    Article  PubMed  CAS  Google Scholar 

  90. Uchino S, Noguchi S, Kawamoto H, et al. Familial nonmedullary thyroid carcinoma characterized by multifocality and a high recurrence rate in a large study population. World J Surg 2002; 26(8):897–902.

    Article  PubMed  Google Scholar 

  91. Van De Velde CJH, Hamming JF, Goslings BM, et al. Report of the consensus development conference on the management of differentiated thyroid cancer in the Netherlands. Eur J Cancer Clin Oncol 1988; 24:287–292.

    Article  Google Scholar 

  92. Baldet L, Manderscheid JC, Glinoer D, Jaffiol C, Coste Seignovert B, Percheron C. The management of differentiated thyroid cancer in Europe in 1988. Results of an international survey. Acta Endocrinol (Copenh) 1989; 120:547–558.

    PubMed  CAS  Google Scholar 

  93. Solomon BL, Wartofsky L, Burman KD. Current trends in the management of well differentiated papillary thyroid carcinoma. J Clin Endocrinol Metab 1996; 81:333–339.

    Article  PubMed  CAS  Google Scholar 

  94. Frankenthaler RA, Sellin RV, Cangir A, Goepfert H. Lymph node metastasis from papillary-follicular thyroid carcinoma in young patients. Am J Surg 1990; 160:341–343.

    PubMed  CAS  Google Scholar 

  95. Agostini L, Mazzi P, Cavaliere A. Multiple primary malignant tumours: gemistocytic astrocytoma with leptomeningeal spreading and papillary thyroid carcinoma. A case report. Acta Neurol (Napoli) 1990; 12:305–310.

    CAS  Google Scholar 

  96. Soravia C, Sugg SL, Berk T, et al. Familial adenomatous polyposis-associated thyroid cancer — A clinical, pathological, and molecular genetics study. Am J Pathol 1999; 154:127–135.

    PubMed  CAS  Google Scholar 

  97. Marsh DJ, Dahia PLM, Caron S, et al. Germline PTEN mutations in Cowden syndrome-like families. J Med Genet 1998; 35:881–885.

    Article  PubMed  CAS  Google Scholar 

  98. Hegedus L. Clinical practice. The thyroid nodule. N Engl J Med 2004; 351(17):1764–1771.

    Article  PubMed  Google Scholar 

  99. Papini E, Guglielmi R, Bianchini A, et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab 2002; 87(5):1941–1946.

    Article  PubMed  CAS  Google Scholar 

  100. Gorges R, Eising EG, Fotescu D, et al. Diagnostic value of high-resolution B-mode and power-mode sonography in the follow-up of thyroid cancer. Eur J Ultrasound 2003; 16(3):191–206.

    Article  PubMed  Google Scholar 

  101. Belfiore A, La Rosa GL, LaPorta GA, et al. Cancer risk in patients with cold thyroid nodules: Relevance of iodine intake, sex, age and multinodularity. Am J Med 1992; 93:363–369.

    Article  PubMed  CAS  Google Scholar 

  102. Mandel SJ. A 64-year-old woman with a thyroid nodule. JAMA 2004; 292(21):2632–2642.

    Article  PubMed  CAS  Google Scholar 

  103. Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med 1993; 328:553–559.

    Article  PubMed  CAS  Google Scholar 

  104. Alexander EK, Heering JP, Benson CB, et al. Assessment of nondiagnostic ultrasound-guided fine needle aspirations of thyroid nodules. J Clin Endocrinol Metab 2002; 87(11):4924–4927.

    Article  PubMed  CAS  Google Scholar 

  105. Massoll N, Nizam MS, Mazzaferri EL. Cystic thyroid nodules: diagnostic and therapeutic dilemmas. Endocrinologist 2002; 12(3):185–198.

    Google Scholar 

  106. Elisei R, Bottici V, Luchetti F, et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10 864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 2004; 89(1):163–168.

    Article  PubMed  CAS  Google Scholar 

  107. Bonnema SJ, Bennedbaek FN, Ladenson PW, Hegedus L. Management of the nontoxic multinodular goiter: a North American survey. J Clin Endocrinol Metab 2002; 87(1):112–117.

    Article  PubMed  CAS  Google Scholar 

  108. Brandi ML, Gagel RF, Angeli A, et al. CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2. J Clin Endocrinol Metab 2001; 86(12): 5658–5671.

    Article  PubMed  CAS  Google Scholar 

  109. Machens A, Niccoli-Sire P, Hoegel J, et al. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 2003; 349(16):1517–1525.

    Article  PubMed  CAS  Google Scholar 

  110. NCCN Thyroid Cancer Practice Guidelines. Oncology 13Supplement 11A, NCCN Proceedings http://www.nccn.org/physician_gls/f_guidelines.html. 1999.

    Google Scholar 

  111. British Thyroid Association. Guidelines for the Management of Differentiated Thyroid Cancer in adults. http://www.british-thyroid-association.org/guidelines.htm. 2002.

    Google Scholar 

  112. Hundahl SA, Cady B, Cunningham MP, et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. US and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer 2000; 89(1):202–217.

    Article  PubMed  CAS  Google Scholar 

  113. Shah JP, Loree TR, Dharker D, et al. Prognostic factors in differentiated carcinoma of the thyroid gland. Am J Surg 1993; 164:658–661.

    Google Scholar 

  114. Mazzaferri EL. NCCN thyroid carcinoma practice guidelines. Oncology 1999; 13Supplement 11A, NCCN Proceedings http://www.nccn.org/physician_gls/f_guidelines.html:391–442.

    Google Scholar 

  115. Noguchi S, Murakami N, Yamashita H, Toda M, Kawamoto H. Papillary thyroid carcinoma — modified radical neck dissection improves prognosis. Arch Surg 1998; 133:276–280.

    Article  PubMed  CAS  Google Scholar 

  116. Hay ID. Papillary thyroid carcinoma. Endocrinol Metab Clin North Am 1990; 19(3):545–576.

    PubMed  CAS  Google Scholar 

  117. Baloch Z, Carayon P, Conte-Devolx B, et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 2003; 13(1):3–126.

    Article  PubMed  Google Scholar 

  118. Koh JM, Kim ES, Ryu JS, Hong SJ, Kim WB, Shong YK. Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparative study. Clin Endocrinol (Oxf) 2003; 58(4):421–427.

    Article  CAS  Google Scholar 

  119. Robbins RJ, Larson SM, Sinha N, et al. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. J Nucl Med 2002; 43(11):1482–1488.

    PubMed  CAS  Google Scholar 

  120. Dragoiescu C, Hoekstra OS, Kuik DJ, et al. Feasibility of a randomized trial on adjuvant radio-iodine therapy in differentiated thyroid cancer. Clin Endocrinol (Oxf) 2003; 58(4):451–455.

    Article  CAS  Google Scholar 

  121. Mazzaferri E. A randomized trial of remnant ablation-in search of an impossible dream? J Clin Endocrinol Metab 2004; 89(8):3662–3664.

    Article  PubMed  CAS  Google Scholar 

  122. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004; 89(8):3668–3676.

    Article  PubMed  CAS  Google Scholar 

  123. Johansen K, Woodhouse NJ, Odugbesan O. Comparison of 1073 MBq and 3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer. J Nucl Med 1991; 32:252–254.

    PubMed  CAS  Google Scholar 

  124. Bal CS, Kumar A, Pant GS. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients. J Clin Endocrinol Metab 2004; 89(4):1666–1673.

    Article  PubMed  CAS  Google Scholar 

  125. Ladenson PW, Braverman LE, Mazzaferri EL, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 1997; 337:888–896.

    Article  PubMed  CAS  Google Scholar 

  126. Pacini F, Molinaro E, Castagna MG, et al. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 2002; 87(9):4063–4068.

    Article  PubMed  CAS  Google Scholar 

  127. Barbaro D, Boni G, Meucci G, et al. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab 2003; 88(9):4110–4115.

    Article  PubMed  CAS  Google Scholar 

  128. Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 2002; 26(8):879–885.

    Article  PubMed  Google Scholar 

  129. Samaan NA, Schultz PN, Hickey RC, Haynie TP, Johnston DA, Ordonez NG. Well-differentiated thyroid carcinoma and the results of various modalities of treatment. A retrospective review of 1599 patients. J Clin Endocrinol Metab 1992; 75:714–720.

    Article  PubMed  CAS  Google Scholar 

  130. Chow SM, Law SC, Mendenhall WM, et al. Papillary thyroid carcinoma: prognostic factors and the role of radioiodine and external radiotherapy. Int J Radiat Oncol Biol Phys 2002; 52(3):784–795.

    Article  PubMed  Google Scholar 

  131. Bernier MO, Leenhardt L, Hoang C, et al. Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocrinol Metab 2001; 86(4):1568–1573.

    Article  PubMed  CAS  Google Scholar 

  132. Schlumberger M, Challeton C, De Vathaire F, et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 1996; 37:598–605.

    PubMed  CAS  Google Scholar 

  133. Taylor T, Specker B, Robbins J, et al. Outcome after treatment of high-risk papillary and non-Hurthle-cell follicular thyroid carcinoma. Ann Intern Med 1998; 129:622–627.

    PubMed  CAS  Google Scholar 

  134. Tsang TW, Brierley JD, Simpson WJ, Panzarella T, Gospodarowicz MK, Sutcliffe SB. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer 1998; 82:375–388.

    Article  PubMed  CAS  Google Scholar 

  135. Hodgson DC, Brierley JD, Tsang RW, Panzarella T. Prescribing 131iodine based on neck uptake produces effective thyroid ablation and reduced hospital stay. Radiother Oncol 1998; 47:325–330.

    Article  PubMed  CAS  Google Scholar 

  136. Sisson JC. Practical dosimetry of 131I in patients with thyroid carcinoma. Cancer Biother Radiopharm 2002; 17(1):101–105.

    Article  PubMed  CAS  Google Scholar 

  137. Maxon HR, Englaro EE, Thomas SR, et al. Radioiodine-131 therapy for well-differentiated thyroid cancer — a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med 1992; 33: 1132–1136.

    PubMed  Google Scholar 

  138. Brierley J, Maxon HR. Radioiodine and external radiation therapy. In: Fagin JA (ed.) Thyroid cancer. Boston/Dordrecht, London: Kluwer Academic Publishers, 1998: 285–317.

    Google Scholar 

  139. Van Nostrand D, Atkins F, Yeganeh F, Acio E, Bursaw R, Wartofsky L. Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. Thyroid 2002; 12(2):121–134.

    Article  PubMed  Google Scholar 

  140. Maxon HR, Thomas SR, Hertzberg VS, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983; 309:937–941.

    Article  PubMed  CAS  Google Scholar 

  141. Koong SS, Reynolds JC, Movius EG, et al. Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma. J Clin Endocrinol Metab 1999; 84:912–916.

    Article  PubMed  CAS  Google Scholar 

  142. Randolph GW, Daniels GH. Radioactive iodine lobe ablation as an alternative to completion thyroidectomy for follicular carcinoma of the thyroid. Thyroid 2002; 12(11):989–996.

    Article  PubMed  Google Scholar 

  143. Burmeister LA, duCret RP, Mariash CN. Local reactions to radioiodine in the treatment of thyroid cancer. Am J Med 1991; 90:217–222.

    PubMed  CAS  Google Scholar 

  144. Alexander C, Bader JB, Schaefer A, Finke C, Kirsch CM. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. J Nucl Med 1998; 39:1551–1554.

    PubMed  CAS  Google Scholar 

  145. Kloos RT, Duvuuri V, Jhiang SM, Cahill KV, Foster JA, Burns JA. Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. J Clin Endocrinol Metab 2002; 87(12):5817–5820.

    Article  PubMed  CAS  Google Scholar 

  146. Burns JA, Morgenstern KE, Cahill KV, Foster JA, Jhiang SM, Kloos RT. Nasolacrimal obstruction secondary to I(131) therapy. Ophthal Plast Reconstr Surg 2004; 20(2):126–129.

    PubMed  CAS  Google Scholar 

  147. Vargas GE, Uy H, Bazan C, Guise TA, Bruder JM. Hemiplegia after thyrotropin alfa in a hypothyroid patient with thyroid carcinoma metastatic to the brain. J Clin Endocrinol Metab 1999; 84:3867–3871.

    Article  PubMed  CAS  Google Scholar 

  148. Datz FL. Cerebral edema following iodine-131 therapy for thyroid carcinoma metastatic to the brain. J Nucl Med 1986; 27:637–640.

    PubMed  CAS  Google Scholar 

  149. Chiu AC, Delpassand ES, Sherman SI. Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab 1997; 82:3637–3642.

    Article  PubMed  CAS  Google Scholar 

  150. Levenson D, Gulec S, Sonenberg M, Lai E, Goldsmith SJ, Larson SM. Peripheral facial nerve palsy after highdose radioiodine therapy in patients with papillary thyroid carcinoma. Ann Intern Med 1994; 120:576–578.

    PubMed  CAS  Google Scholar 

  151. Van Nostrand D, Neutze J, Atkins F. Side effects of “rational dose” iodine-131 therapy for metastatic welldifferentiated thyroid carcinoma. J Nucl Med 1986; 27: 1519–1527.

    PubMed  Google Scholar 

  152. Dorn R, Kopp J, Vogt H, Heidenreich P, Carroll RG, Gulec SA. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J Nucl Med 2003; 44(3):451–456.

    PubMed  CAS  Google Scholar 

  153. Raymond JP, Izembart M, Marliac V, et al. Temporary ovarian failure in thyroid cancer patients after thyroid remnant ablation with radioactive iodine. J Clin Endocrinol Metab 1989; 69:186–190.

    PubMed  CAS  Google Scholar 

  154. Schlumberger M, De Vathaire F, Ceccarelli C, et al. Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. J Nucl Med 1996; 37:606–612.

    PubMed  CAS  Google Scholar 

  155. Dottorini ME, Lomuscio G, Mazzucchelli L, Vignati A, Colombo L. Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma. J Nucl Med 1995; 36:21–27.

    PubMed  CAS  Google Scholar 

  156. Ceccarelli C, Bencivelli W, Morciano D, Pinchera A, Pacini F. 131I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: results of a retrospective study. J Clin Endocrinol Metab 2001; 86(8): 3512–3515.

    Article  PubMed  CAS  Google Scholar 

  157. Vini L, Hyer S, Al Saadi A, Pratt B, Harmer C. Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer. Postgrad Med J 2002; 78(916):92–93.

    Article  PubMed  CAS  Google Scholar 

  158. Sarkar SD, Beierwaltes WH, Gill SP, Cowley BJ. Subsequent fertility and birth histories of children and adolescents treated with 131I for thyroid cancer. J Nucl Med 1976; 17:460–464.

    PubMed  CAS  Google Scholar 

  159. Mazzaferri EL. Gonadal damage from 131I therapy for thyroid cancer. Clin Endocrinol (Oxf) 2002; 57(3):313–314.

    Article  Google Scholar 

  160. Handelsman DJ, Turtle JR. Testicular damage after radioactive iodine (I-131) therapy for thyroid cancer. Clin Endocrinol 1983; 18:465–472.

    CAS  Google Scholar 

  161. Pacini F, Gasperi M, Fugazzola L, et al. Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine. J Nucl Med 1994; 35:1418–1422.

    PubMed  CAS  Google Scholar 

  162. Hyer S, Vini L, O’Connell M, Pratt B, Harmer C. Testicular dose and fertility in men following I(131) therapy for thyroid cancer. Clin Endocrinol (Oxf) 2002; 56(6): 755–758.

    Article  CAS  Google Scholar 

  163. Edmonds CJ, Smith T. The long-term hazards of the treatment of thyroid cancer with radioiodine. Br J Radiol 1986; 59:45–51.

    PubMed  CAS  Google Scholar 

  164. Gunter HH, Schober O, Schwarzrock R, Hundeshagen H. Hematologic long-term modifications after radioiodine therapy in carcinoma of the thyroid gland. II. Modifications of the bone marrow including leukemia. Strahlentherapie und Onkologie 1986; 163:475–485.

    Google Scholar 

  165. Maxon H, III, Smith HS. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metabol Clin North Am 1990; 19:685–718.

    Google Scholar 

  166. Wong JB, Kaplan MM, Meyer KB, Pauker SG. Ablative radioactive iodine therapy for apparently localized thyroid carcinoma. A decision analytic perspective. Endocrinol Metabol Clin North Am 1990; 19:741–760.

    CAS  Google Scholar 

  167. Brown AP, Greening WP, McCready VR, Shaw HJ, Harmer CL. Radioiodine treatment of metastatic thyroid carcinoma: the Royal Marsden Hospital experience. Br J Radiol 1984; 57:323–327.

    Article  PubMed  CAS  Google Scholar 

  168. Cooper DS, Specker B, Ho M, et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 1998; 8(9):737–744.

    PubMed  CAS  Google Scholar 

  169. Maloof F, Vickery AL, Rapp B. An evaluation of various factors influencing the treatment of metastatic thyroid carcinoma with I 131. J Clin Endocrinol Metab 1956; 16(1):1–27.

    PubMed  CAS  Google Scholar 

  170. Mazzaferri EL. Thyroid cancer in thyroglossal duct remnants: a diagnostic and therapeutic dilemma. Thyroid 2004; 14(5):335–336.

    Article  PubMed  Google Scholar 

  171. Dulgeroff AJ, Hershman JM. Medical therapy for differentiated thyroid carcinoma. Endocrinol Rev 1994; 15:500–515.

    Article  CAS  Google Scholar 

  172. Faber J, Galloe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: A meta-analysis.Acta Endocrinol (Copenh) 1994; 130:350–356.

    CAS  Google Scholar 

  173. Uzzan B, Campos J, Cucherat M, Nony P, Boissel JP, Perret GY. Effects on bone mass of long term treatment with thyroid hormones: A meta-analysis. J Clin Endocrinol Metab 1996; 81:4278–4289.

    Article  PubMed  CAS  Google Scholar 

  174. Marcocci C, Golia F, Vignali E, Pinchera A. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine. J Bone Miner Res 1997; 12:72–77.

    Article  PubMed  CAS  Google Scholar 

  175. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994; 331: 1249–1252.

    Article  PubMed  CAS  Google Scholar 

  176. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 2001; 358(9285):861–865.

    Article  PubMed  CAS  Google Scholar 

  177. Biondi B, Fazio S, Carella C, et al. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1993; 77:334–338.

    Article  PubMed  CAS  Google Scholar 

  178. Fazio S, Biondi B, Carella C, et al. Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: Beneficial effect of βblockade. J Clin Endocrinol Metab 1995; 80:2222–2226.

    Article  PubMed  CAS  Google Scholar 

  179. Shapiro LE, Sievert R, Ong L, et al. Minimal cardiac effects in asymptomatic athyreotic patients chronically treated with thyrotropin-suppressive doses of L-thyroxine. J Clin Endocrinol Metab 1997; 82:2592–2595.

    Article  PubMed  CAS  Google Scholar 

  180. Bartalena L, Martino E, Pacchiarotti A, et al. Factors affecting suppression of endogenous thyrotropin secretion by thyroxine treatment: retrospective analysis in athyreotic and goitrous patients. J Clin Endocrinol Metab 1987; 64:849–855.

    Article  PubMed  CAS  Google Scholar 

  181. Burmeister LA, Goumaz MO, Mariash CN, Oppenheimer JH. Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 1992; 75:344–350.

    Article  PubMed  CAS  Google Scholar 

  182. Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jaffiol C. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 1996; 81:4318–4323.

    Article  PubMed  CAS  Google Scholar 

  183. Cooper DS, Specker B, Ho M, et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: Results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 1999; 8:737–744.

    Article  Google Scholar 

  184. Schlumberger M, Berg G, Cohen O, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 2004; 150(2):105–112.

    Article  PubMed  CAS  Google Scholar 

  185. Mazzaferri EL, Kloos RT. Using recombinant human TSH in the management of well-differentiated thyroid cancer: current strategies and future directions. Thyroid 2000; 10(9):767–778.

    PubMed  CAS  Google Scholar 

  186. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999; 84:3877–3885.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, The Ohio State University, Columbus, OH

    Ernest L. Mazzaferri MD, MACP

  2. Department of Medicine, University of Florida, Gainesville, FL, USA

    Ernest L. Mazzaferri MD, MACP

Authors
  1. Ernest L. Mazzaferri MD, MACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Ohio State University, Columbus, OH, USA

    Ernest L. Mazzaferri MD, MACP (Emeritus Professor) (Emeritus Professor)

  2. University of Florida, Gainsville, FL, USA

    Ernest L. Mazzaferri MD, MACP (Emeritus Professor) (Emeritus Professor)

  3. Department of Radiotherapy, Royal Marsden Hospital, London, UK

    Clive Harmer FRCR, FRCP (Head of Thyroid Unit) (Head of Thyroid Unit)

  4. Northern Centre for Cancer Treatment, Newcastle upon Tyne, UK

    Ujjal K. Mallick MS, FRCR (Vice-Chair) (Vice-Chair)

  5. Thyroid Cancer Subgroup, National Cancer Research Institute, UK

    Ujjal K. Mallick MS, FRCR (Vice-Chair) (Vice-Chair)

  6. Northern Cancer Network Thyroid Cancer Group, UK

    Ujjal K. Mallick MS, FRCR (Vice-Chair) (Vice-Chair)

  7. Department of Medicine, University of Newcastle upon Tyne, UK

    Pat Kendall-Taylor MD, FRCP (Emeritus Professor) (Emeritus Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag London Limited

About this chapter

Cite this chapter

Mazzaferri, E.L. (2006). An Overview of the Management of Thyroid Cancer. In: Mazzaferri, E.L., Harmer, C., Mallick, U.K., Kendall-Taylor, P. (eds) Practical Management of Thyroid Cancer. Springer, London. https://doi.org/10.1007/1-84628-013-3_1

Download citation

  • DOI: https://doi.org/10.1007/1-84628-013-3_1

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-85233-910-4

  • Online ISBN: 978-1-84628-013-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation